Stericycle, Inc.

NasdaqGS:SRCL Aktierapport

Börsvärde: US$5.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stericycle Förvaltning

Förvaltning kriterier kontrolleras 4/4

Stericycle VD är Cindy Miller, utsedd i Oct 2018, har en mandatperiod på 6.08 år. totala årliga ersättningen är $ 7.29M, bestående av 14.7% lön 85.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.13% av företagets aktier, värda $ 7.25M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.8 år respektive 5.7 år.

Viktig information

Cindy Miller

Verkställande direktör

US$7.3m

Total ersättning

VD-lön i procent14.66%
Anställning som VD6.1yrs
Ägande av VD0.1%
Ledningens genomsnittliga anställningstid5.8yrs
Styrelsens genomsnittliga mandatperiod5.7yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Stericycle: Watch Potential Revenue Recovery And Margin Improvement

Summary SRCL's Q1 2024 operating margins beat expectations, and the company's EBITDA margin is expected to improve significantly for full-year 2024. I anticipate that Stericycle's Secure Information Destruction segment can realize a turnaround due to a more favorable base for YoY comparison in 2H and the introduction of a subscription service. My Buy rating for SRCL stays intact following an assessment of its outlook and valuations. Read the full article on Seeking Alpha
Seeking Alpha • Mar 03

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Summary Stericycle's normalized EPS grew by +26% QoQ in Q4 2023, and this translated into a +14% bottom line beat. The company is anticipating that its earnings will expand strongly by +24% in this new fiscal year, which is better than what Wall Street had anticipated earlier. I stick to a Buy investment rating for Stericycle stock, as I have greater confidence in SRCL's long-term prospects after reviewing its Q4 results and 2024 guidance. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Stericycle: Muted Outlook, Fair Valuations

Summary Stericycle's revenue outlook is murky, the recovery for the secure information destruction business is still in progress, but the regulated waste and compliance segment might be affected by staffing shortages. SRCL should still record lower earnings for FY 2022 vis-a-vis FY 2021 despite delivering an EPS beat in Q2, due to higher operating and interest expenses. I continue to assign a Hold rating to Stericycle, as its valuations are reasonably fair and aligned with its full-year outlook. Elevator Pitch I rate Stericycle, Inc.'s (SRCL) stock as a Hold. I evaluated SRCL's pace of recovery from the pandemic and its capital allocation plans in an earlier October 22, 2021 article for the stock. I focus on the near-term expectations for Stericycle in this update. My analysis leads me to the conclusion that the consensus earnings forecasts implying a mid-single digit percentage decline for SRCL in FY 2022 are realistic, and Stericycle's current valuations seem to be fair taking into account the full-year outlook. As such, I maintain a Hold rating for SRCL. Revisions To Consensus Estimates The recent changes to the sell-side's consensus bottom line forecasts for Stericycle provide an indication of what the market expects of SRCL's future performance. The consensus Q3 2022 normalized earnings per share or EPS for SRCL has been revised upwards by a substantial +11% in the past one month. It is reasonable to assume that the Wall Street analysts had raised their third-quarter bottom line projections for the company in response to Stericycle's +9% EPS beat for Q2 2022. It is worthy of note that SRCL has had earnings misses for the prior four quarters between Q2 2021 and Q1 2022. But the full-year fiscal 2022 consensus numbers tell a different story. In the last one month, the market's consensus FY 2022 normalized EPS estimate ($2.06) for Stericycle has in fact been reduced slightly by -0.5%, notwithstanding SRCL's second-quarter earnings beat. Moreover, four of the eight analysts covering SRCL's shares actually lowered their EPS estimates for the company in the past month. The analysts' less than favorable view of Stericycle's full-year FY 2022 outlook might be linked to the company's most recently updated management guidance. At its Q2 2022 earnings call in early-August 2022, SRCL increased the mid-point of its FY 2022 revenue growth guidance from +4% to +5%, but it lowered the mid-point of its full-year EPS guidance from $2.15 to $2.075 (implying a -5% decline as compared to 2021 EPS of $2.19). In the rest of the article, I will assess the growth prospects of its two key business segment and the company's overall profitability. This will help to explain why company management and analysts are of the opinion that Stericycle's bottom line for FY 2022 will still contract despite above-expectations Q2 2022 earnings. Secure Information Destruction Business Performed Well in Q2 Organic revenue for Stericycle's secure information destruction business, adjusted to exclude inorganic transactions and foreign exchange effects, expanded by an impressive +12.2% YoY for the second quarter of 2022. The expectations for SRCL's secure information destruction segment weren't high, as this business faces structural challenges relating to reduced paper usage in an increasingly digitalized world. However, the company's business secure information destruction business has witnessed a meaningful recovery in Q2 2022, as pandemic restrictions are eased and an increasing number of workers return to offices. More critically, the current recovery for the secure information destruction segment still has legs to run. Stericycle highlighted at its second-quarter results briefing that "I don't think the industry has settled yet in terms of everybody being back to what is the new normal." In other words, SRCL is implying that there could be a further acceleration in the pace of people going back to offices in time to come, and this will be positive for the secure information destruction business' near-term outlook. Disappointing Performance For Regulated Waste And Compliance Services Segment In contrast with the double-digit top line growth for the secure information destruction segment in the recent quarter, Stericycle's other segment, the regulated waste and compliance services business disappointed investors with its Q2 2022 results. Specifically, the regulated waste and compliance services segment saw a very modest +1.8% YoY increase in its second-quarter organic revenue. Notably, SRCL mentioned at its Q2 2022 earnings briefing that "most of the growth" for the company's regulated waste and compliance services segment for the most recent quarter "was due to pricing." This suggests that volumes for this business was probably flattish on a YoY basis in the second quarter of this year. There are two key factors that explain why the regulated waste and compliance services business' volumes haven't grown in a meaningful way in the recent quarter. Firstly, there was a decline in COVID-19 testing and vaccinations in Q2, as COVID-19 transitions gradually into an endemic state. Secondly, the labor crunch has also affected the healthcare industry, which means that it is tough for the number of elective surgeries to return to similar levels seen before the pandemic anytime soon. Future Profitability Hurt By Operating Cost Pressures And Higher Interest Rates As discussed in an earlier section of the article, Stericycle cut its full-year FY 2022 bottom line guidance after it reported its Q2 2022 earnings. SRCL attributed this change to "higher cash operating and interest expenses" at its most recent quarterly investor call.
Seeking Alpha • Aug 04

Stericycle Q2 2022 Earnings Preview

Stericycle (NASDAQ:SRCL) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.44 (-34.3% Y/Y) and the consensus Revenue Estimate is $678.27M (+0.8% Y/Y). Over the last 2 years, SRCL has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 2 upward revisions and 1 downward.
Seeking Alpha • Jun 03

Stericycle: The Risks Outweigh The Reward

Stericycle seems to be in a continued state of decline, even though the pandemic is largely over. If shares were cheap enough, the company might be worth the risk, but that isn't the case either. Add in regulatory risks moving forward, and it's not worth the risk playing this name right now.
Seeking Alpha • Oct 22

Stericycle: A Neutral View

I am negative on SRCL's recovery prospects in the short term, as there has been a delay in the return of workers back to office. But I have a favorable opinion of Stericycle's capital allocation initiatives in relation to debt reduction and business or asset sales. Stericycle currently trades at consensus forward FY 2021 and FY 2022 normalized P/E multiples of 26.9 times and 25.2 times, respectively, and this seems expensive.
Seeking Alpha • Aug 08

Stericycle: A Successful Turnaround Is Likely

Revenues declined in 2018, 2019, and 2020 as the company is divesting some businesses. Long-term debt has dramatically declined in recent quarters. The company is highly profitable. Shares are down by ~55% from all-time highs in 2015. This is a turnaround play worth the risk at this price.

Analys av ersättningar till VD

Hur har Cindy Miller:s ersättning förändrats jämfört med Stericycle:s resultat?
DatumTotal ersättningLönFöretagets resultat
Sep 30 2024n/an/a

US$20m

Jun 30 2024n/an/a

US$36m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$7mUS$1m

-US$21m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

US$22m

Mar 31 2023n/an/a

US$81m

Dec 31 2022US$7mUS$1m

US$56m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$68m

Dec 31 2021US$7mUS$1m

-US$28m

Sep 30 2021n/an/a

US$38m

Jun 30 2021n/an/a

US$23m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$6mUS$937k

-US$57m

Sep 30 2020n/an/a

-US$325m

Jun 30 2020n/an/a

-US$303m

Mar 31 2020n/an/a

-US$329m

Dec 31 2019US$3mUS$805k

-US$347m

Sep 30 2019n/an/a

-US$446m

Jun 30 2019n/an/a

-US$369m

Mar 31 2019n/an/a

-US$312m

Dec 31 2018US$2mUS$156k

-US$253m

Ersättning vs marknad: Cindy s total kompensation ($USD 7.29M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 8.38M ).

Ersättning vs inkomst: Ersättningen från Cindy har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Cindy Miller (61 yo)

6.1yrs
Anställning
US$7,290,832
Kompensation

Ms. Cindy J. Miller serves as Independent Director of W.W grainger inc since April 24, 2024. She served as an Independent Director at UGI Corporation since September 1, 2020 until March 25, 2024. Ms. Mille...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Cindy Miller
President6.1yrsUS$7.29m0.13%
$ 7.2m
Janet Zelenka
Executive VP5.4yrsUS$3.67m0.056%
$ 3.2m
Kurt Rogers
Executive VP7.3yrsUS$2.04m0.036%
$ 2.1m
Daniel Ginnetti
Executive Vice President of International6.4yrsUS$2.24m0.045%
$ 2.6m
Stephen White
Executive VP & Chief Commercial Officer5.1yrsUS$1.85m0.027%
$ 1.6m
Richard Hoffman
Senior VP & Chief Accounting Officer7.5yrsinga uppgifter0.023%
$ 1.3m
Andrew Ellis
Vice President of Investor Relations4.3yrsinga uppgifteringa uppgifter
Michael Weisman
Executive VP and Chief Ethics & Compliance Officer6.6yrsinga uppgifter0.022%
$ 1.3m
Joseph Reuter
Executive VP & Chief People Officer5.8yrsUS$938.00k0.035%
$ 2.0m
Richard Moore
Executive Vice President of North American Operations5.8yrsinga uppgifter0.026%
$ 1.5m
Dominic Culotta
Executive VP & Chief Transformation Officer5.6yrsinga uppgifter0.023%
$ 1.3m
Cara Simaga
Director of Government Affairsno datainga uppgifteringa uppgifter
5.8yrs
Genomsnittlig anställningstid
60.5yo
Genomsnittlig ålder

Erfaren ledning: SRCL s ledningsgrupp är erfaren och erfaren ( 5.8 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Cindy Miller
President5.8yrsUS$7.29m0.13%
$ 7.2m
Thomas Chen
Independent Director10.5yrsUS$242.47k0.022%
$ 1.3m
Brian Anderson
Independent Director7.8yrsUS$267.47k0.017%
$ 997.8k
Naren Gursahaney
Independent Director1.8yrsUS$293.74k0.0065%
$ 371.7k
Robert Murley
Independent Chairman of the Board7.8yrsUS$367.48k0.0057%
$ 328.0k
James Welch
Independent Director4.5yrsUS$262.47k0.012%
$ 671.5k
Stephen Hooley
Independent Director5.7yrsUS$262.38k0%
$ 0
Victoria Dolan
Independent Director1.5yrsUS$202.47k0%
$ 0
Lynn Bleil
Independent Director9.5yrsUS$262.47k0.0027%
$ 153.1k
J. Hackney
Independent Director5.7yrsUS$242.47k0.014%
$ 832.6k
5.7yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder

Erfaren styrelse: SRCL s styrelse anses vara erfaren ( 5.7 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2024/11/04 13:02
Aktiekurs vid dagens slut2024/11/01 00:00
Intäkter2024/09/30
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Stericycle, Inc. bevakas av 21 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Gary BisbeeBarclays
Alexander ParisBarrington Research Associates, Inc.
Kevin SteinkeBarrington Research Associates, Inc.